Abstract
AIM: To study the association between diabetes and the prevalence of and risk factors for polypharmacy among adults aged 50 and older in England.
METHODS: A cross-sectional study (2012-2013) of the English Longitudinal Study of Ageing. Polypharmacy was defined as taking 5-9 long-term medications a day and heightened polypharmacy as 10 or more. Diabetes included diagnosed and undiagnosed cases (glycated haemoglobin ≥ 6.5% (48 mmol/mol)).
RESULTS: Of 7729 participants, 1100 people had diabetes and showed higher prevalence rates of polypharmacy (41.1% vs 14.8%) and heightened polypharmacy (5.8% vs 1.7%) than those without diabetes, even when antihyperglycemic medications were excluded. Risk factors for polypharmacy also differed according to diabetes status. Among people with diabetes, risk factors for polypharmacy and heightened polypharmacy were having more long-term conditions (relative risk ratio (RRR) = 1.86; 3.51) and being obese (RRR = 1.68; 3.68), while females were less likely to show polypharmacy (RRR = 0.51) and heightened polypharmacy (RRR = 0.51) than males. Older age (RRR = 1.04) was only related to polypharmacy among people without diabetes.
CONCLUSIONS: Adults with diabetes had higher prevalence rates of polypharmacy and heightened polypharmacy than those without diabetes, regardless of including antihyperglycemic drugs. Early detection of polypharmacy among older people with diabetes needs to focus on co-morbidities and obesity.
Original language | English |
---|---|
Pages (from-to) | 108842 |
Journal | Diabetes Research and Clinical Practice |
Volume | 176 |
Early online date | 29 Apr 2021 |
DOIs | |
Publication status | Published - Jun 2021 |
Keywords
- Aged
- Aged, 80 and over
- Aging/physiology
- Comorbidity
- Cross-Sectional Studies
- Diabetes Complications/drug therapy
- Diabetes Mellitus/drug therapy
- England/epidemiology
- Female
- Glycated Hemoglobin A/metabolism
- Humans
- Hypoglycemic Agents/therapeutic use
- Longitudinal Studies
- Male
- Middle Aged
- Obesity/complications
- Polypharmacy
- Prevalence
- Risk Factors